Teva meets main goal in trial for its migraine prevention in children and adolescents
https://seekingalpha.com/news/4125459-teva-meets-main-goal-in-trial-for-its-migraine-prevention-in-children-and-adolescents?source=feed_tag_israel
Jul 18, 2024 - Teva Pharmaceutical's AJOVY (fremanezumab) shows positive results in preventing episodic migraines in children and adolescents aged 6-17 years.
0
Argus upgrades Teva to buy, cites recent drug approvals
https://seekingalpha.com/news/4123365-argus-upgrades-teva-to-buy-cites-recent-drug-approvals?source=feed_tag_israel
Jul 10, 2024 - Argus has upgraded Teva (TEVA) to buy, citing valuation and new product approvals. Read more here.
0
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
https://www.zacks.com/commentary/2299360/3-generic-drug-stocks-to-watch-amid-improving-market-prospects?cid=CS-ZC-FT-industry_outlook-2299360
Jul 10, 2024 - With the ease in inflationary pressure, the Zacks Medical - Generic Drugs industry is expected to benefit from declining costs. New product launches provide some respite to AMPH, RDY, and TEVA.
0
Teva focus of FTC investigation over inhaler patents
https://seekingalpha.com/news/4121149-teva-focus-ftc-investigation-inhaler-patents?source=feed_tag_israel
Jul 01, 2024 - The FTC has launched an investigation into Teva Pharmaceutical's refusal to withdraw patents allegedly delaying generic competition for asthma and COPD inhalers. read more here.
0
Teva to pay $750M as part of tax deal with Israel
https://seekingalpha.com/news/4118806-teva-pay-750m-israel-tax-deal?source=feed_tag_israel
Jun 25, 2024 - Teva Pharmaceutical (TEVA) agrees to pay $750M as part of a settlement with Israel Tax Authority, to resolve tax disputes from 2008-2020. Read more here.
0
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis
https://www.zacks.com/stock/news/2290253/abbvie-s-abbv-skyrizi-gets-fda-nod-for-ulcerative-colitis?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2290253
Jun 19, 2024 - AbbVie's (ABBV) Skyrizi is now approved for four indications across immune-mediated inflammatory diseases.
0
Teva asthma inhaler patents are 'improperly listed' in FDA Orange Book
https://seekingalpha.com/news/4115251-teva-asthma-inhaler-patents-are-improperly-listed-in-fda-orange-book?source=feed_tag_israel
Jun 12, 2024 - A New Jersey judge ruled that Teva's patents for its ProAir HFA inhaler were listed improperly in the FDA's Orange Book, benefiting Amneal Pharmaceuticals.
0
Teva Pharmaceutical Industries Limited (TEVA) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)
https://seekingalpha.com/article/4698647-teva-pharmaceutical-industries-limited-teva-goldman-sachs-45th-annual-global-healthcare?source=feed_tag_israel
Jun 11, 2024 - Teva Pharmaceutical Industries Limited (NYSE:NYSE:TEVA) Goldman Sachs 45th Annual Global Healthcare Conference Call June 11, 2024 8:00 AM ETCompany...
0
Teva Pharmaceutical: Buy This Bargain Before It's Gone
https://seekingalpha.com/article/4698039-teva-pharmaceutical-buy-this-bargain-before-its-gone?source=feed_tag_israel
Jun 07, 2024 - Richard Francis's 'Pivot to Growth' strategy brings success to Teva Pharmaceutical as they expand their portfolio. Learn more about TEVA stock here.
0
TEVA Stock Rises 135% in a Year: What's Driving the Recovery?
https://www.zacks.com/stock/news/2283544/teva-stock-rises-135-in-a-year-what-s-driving-the-recovery?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2283544
Jun 04, 2024 - TEVA expects its newer drugs, Austedo, Uzedy and Ajovy, as well as a stable generics business, to help revive top-line growth in future quarters.
0